Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

A-GCB); manufacturing and commercialisation including, but not limited to, the establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not limited to, the impact of those on Shire's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialisation and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2007.

The following are trademarks of Shire or companies within the Shire Group which are the subject of trademark registrations in certain territories:

ADDERALL XR(R) (mixed salts of a single-entity amphetamine)

ADDERALL(R) (mixed salts of a single-entity amphetamine)

CALCICHEW(R) range (calcium carbonate with or without vitamin D3)

CARBATROL(R) (carbamazepine) extended-release capsules

DAYTRANA(TM) (methylphenidate transdermal system)

ELAPRASE(R) (idursulfase)

FOSRENOL(R) (lanthanum carbonate)

INTUNIV(TM) (guanfacine) extended release

LIALDA(TM) (mesalamine)

MEZAVANT(R) (mesalazine)

REMINYL(R) (galantamine hydrobromide) (UK and Republic of Ireland)

REMINYL XL(TM) (galantamine hydrobromide) (UK and Republic of Ireland)

REPLAGAL(R) (agalsidase alfa)

VYVANSE(TM) (lisdexamfetamine dimesylate)

XAGRID(R) (anagrelide hydrochloride)

The following are trademarks of third parties referred to in this press release:

3TC (lamivudine) (trademarks of GlaxoSmithKline (GSK))

COMBIVIR (lamivudine) (trademark
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis plc ... pharmaceutical company, and Rhythm, a biopharmaceutical company, today announced ... acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which ... the treatment of diabetic gastroparesis and other GI functional ... Phase 2 trial of relamorelin for the treatment of ...
(Date:10/22/2014)... Involution Studios , a healthcare software ... infographic, Understanding Ebola . The goal of ... to follow informative tool for anyone wanting to know ... prevention. , "As the news has spread in all ... represents not only a healthcare crisis with global impact, ...
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... Today, at the Canadian,Diabetes Association Congress, physicians ... from a phase 3b clinical study (LEAD(TM) 6) ... study showed,that liraglutide, a human GLP-1 analog administered ... glucose control (as,measured by HbA1c) than exenatide, a ...
... researchers from Penn State and the University of Texas Southwestern ... control certain proteins that catalyze biochemical reactions. "This is ... activity of a protein using light," said Stephen Benkovic, Penn ... Family Chair in Chemistry, and one of the team,s leaders. ...
... 16 The Department of Biomedical,Engineering at ... Dr.,Michael Merzenich, one of the world,s premier ... speaker at the semi-annual Allen and,Constance Ford ... in,Cleveland. The program "A revolution in neuro-therapeutics: ...
Cached Biology Technology:New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 2New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 3New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes 4Scientists use light to control proteins 2Brain and Hearing Pioneer, Michael Merzenich, Ph.D. to Speak at Case Western Reserve University 2Brain and Hearing Pioneer, Michael Merzenich, Ph.D. to Speak at Case Western Reserve University 3
(Date:10/17/2014)... in German . ... day in order to reproduce? And why are there two ... the latest issue of the research journal Molecular Human ... Steven Ramm from Bielefeld University Bielefeld has compiled this special ... for a female to copulate with several males in quick ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
Breaking Biology News(10 mins):Sperm wars 2Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2
... Most venomous snakes are legendary for their lethal bites, ... University of Massachusetts Lowell, explains that some cobras defend themselves ... Getting the chance to work with spitting cobras in South ... tracks aimed at his eyes. Protected by a sheet of ...
... Texas May 14, 2010 Scientists studying the ... of Louisiana and the city of New Orleans have ... exposure to chemical contaminants. The findings, published in a ... demonstrate how Hurricane Katrina caused significant ecological damage by ...
... 2010) Novel vaccines for diseases ranging from the ... research at the American Association of Pharmaceutical Scientists, (AAPS) ... government will gather at the Hilton San Francisco Union ... research and advances in biotherapeutics. Researchers from ...
Cached Biology News:Spitting cobras track first, predict later 2New research reveals Hurricane Katrina's impact on ecological and human health 2New research reveals Hurricane Katrina's impact on ecological and human health 3Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference 2
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... important role in the regulation of signaling ... Splice variants have been reported that affect ... apoptotic pathways. With Apoptosis and Cell Death ... expression profiling and at the same time ...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Kit is manufactured for DNA purification from ... to UV light. The Purification of DNA ... for DNA-cloning work. The conventional method of ... of UV light damages DNA and significantly ...
Biology Products: